The approach, described in a study published in Science Advances, is called SHIFTERS. Rather than searching for a naturally occurring antigen that appears exclusively on cancer cells, the system is designed to make tumor cells display one. Its target is CD19, a surface protein already recognized by many clinically developed CAR-T cells. CD19 is normally associated with B cells and is not broadly displayed by solid tumors. SHIFTERS uses a genetic program, combined with the low-oxygen environment characteristic of many tumors and externally applied focused ultrasound, to prompt selected cancer cells to temporarily present CD19 on their surfaces.

The system is built around a two-signal logic gate. The first signal is hypoxia, or low oxygen concentration, a hallmark of rapidly growing solid tumors. As malignant tissue expands, its blood vessels often fail to deliver enough oxygen, creating oxygen-deprived regions within the tumor mass. SHIFTERS is engineered to respond to molecular conditions associated with this hypoxic environment. The second signal is supplied by a physician through focused ultrasound. Because ultrasound can be directed toward tissue beneath the skin without an incision, it provides a spatial control mechanism: the genetic circuit is intended to become active only where tumor biology and the physician’s acoustic instruction coincide.

When both conditions are present, the engineered program activates CD19 production at the tumor-cell surface. This converts previously invisible cancer cells into temporary beacons for CAR-T cells. The T cells do not need to recognize the original biology of the tumor, which may vary widely among patients and cancer types. Instead, they use their existing CD19-specific receptor to identify the primed cells, form an immunological synapse and release cytotoxic molecules such as perforin and granzymes. These molecules damage the target cell and initiate its death. According to the USC team, the induced marker can remain detectable for approximately one week, creating a treatment window during which the location and timing of immune-cell activation can be controlled.

That design addresses a fundamental difficulty in solid-tumor immunotherapy. Blood cancers often carry relatively uniform surface markers that can be targeted throughout the malignant cell population. Solid tumors, by contrast, develop from normal tissues and frequently share many molecular features with healthy cells. Even when a candidate antigen is abundant in a tumor, it may also appear in essential organs, raising the risk of dangerous off-target damage. Tumors are also heterogeneous: different regions, and sometimes different cells within the same tumor, may carry different mutations and surface proteins. A temporary, externally controlled marker could offer a way to separate target recognition from the tumor’s naturally inconsistent antigen landscape.

The researchers evaluated SHIFTERS through a series of preclinical experiments. They first studied the system in cultured cancer cells, where they could measure genetic activation, CD19 display and CAR-T-mediated killing under controlled oxygen and ultrasound conditions. They then moved to three-dimensional tumor models, which reproduce some of the physical barriers found in actual tumors, including dense cellular organization and limited diffusion. Finally, they tested the strategy in animal models carrying human brain and liver tumors. Across these stages, the team reported that ultrasound treatment increased CD19 expression and enabled CAR-T cells to attack tumor tissue more effectively than they did without the priming step.

In animal experiments, tumors exposed to the ultrasound-guided system shrank substantially, while tumors that did not receive the same activation continued to grow. The findings do not yet establish that SHIFTERS will work in patients, but they suggest that the approach can translate a physical treatment signal into a molecular recognition signal. Focused ultrasound is already used in medicine for several purposes, including imaging and selected therapeutic applications, although the acoustic parameters and safety requirements for this system would need to be carefully defined for each tumor type and anatomical location. Treating a brain tumor, for example, introduces additional challenges because the skull can distort and weaken ultrasound waves, while liver and pancreatic tumors may move with respiration.

One of the study’s most notable observations was that not every cancer cell needed to display CD19 for the treatment to produce a broader antitumor response. The team reported that activating the marker on roughly 10% to 25% of tumor cells was sufficient to drive substantial killing in laboratory models. These CD19-positive cells appeared to act as “training centers” or initiating targets for the immune response. After recognizing and destroying them, CAR-T cells and other immune mechanisms may contribute to wider damage across neighboring cancer cells, including cells that never displayed the engineered marker. This effect could be especially important in heterogeneous tumors, where reaching every malignant cell with a genetic therapy may be unrealistic.

The researchers describe this phenomenon as a form of bystander or collateral immune killing, although its exact biological basis will require further investigation. Direct CAR-T recognition of CD19-positive cells may release inflammatory signals, alter the tumor microenvironment and expose additional tumor antigens to the immune system. Dying cancer cells can also release intracellular proteins that are processed and presented to other immune cells, potentially broadening the response beyond the synthetic CD19 target. Whether this amplification remains effective in the immunosuppressive environment of human solid tumors is unknown. Many such tumors contain regulatory immune cells, abnormal blood vessels, fibrotic tissue and metabolic conditions that can restrict T-cell entry and function.

Delivery is currently the largest practical obstacle. SHIFTERS requires tumor cells to receive genetic instructions encoding the hypoxia- and ultrasound-responsive program, and those instructions must reach enough of the tumor without spreading dangerously to healthy tissue. The USC team is comparing lipid nanoparticles with modified viral vectors. Lipid nanoparticles can carry nucleic acids without using a replicating virus and have become important in several biomedical applications, but their distribution and persistence in solid tumors can be uneven. Viral vectors may deliver genes more efficiently to certain cells, yet they introduce additional questions involving immune reactions, dose control, manufacturing and the possibility of unintended expression outside the treatment zone.

The study was conducted in animals and has not yet been tested in people. Before clinical trials could begin, investigators would need to establish reliable delivery, determine how long CD19 expression lasts, define safe ultrasound intensities and evaluate the risk of activating CAR-T cells in healthy tissue. They would also need to study whether repeated treatment is possible, how the therapy behaves in tumors with different oxygen patterns and whether engineered cells can penetrate the tumor at clinically meaningful levels. The work was funded in part by the National Institutes of Health. The authors disclosed that Yi Wang is a scientific co-founder and consultant of Cell E&G Inc. and Acoustic Cell Therapy Inc., while the other authors reported no competing interests.

Despite these limitations, SHIFTERS represents a shift in the way researchers are approaching the antigen problem. Instead of waiting for solid tumors to reveal a perfect natural marker, the strategy seeks to install a temporary one under the direction of tumor physiology and focused ultrasound. Peter Yingxiao Wang, who led the work at USC, said the broader goal is to “rewire” both the tumor and the T cell so they can recognize and destroy one another more effectively. The technology remains years from clinical use and will require larger animal studies, improved delivery systems and rigorous safety testing. But if those hurdles can be overcome, an ultrasound-controlled, temporary antigen could give CAR-T therapy a new route into cancers that have so far remained largely beyond its reach.

Subject of Research: Animals

Article Title: Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy

News Publication Date: 10-Jun-2026

Web References: https://www.science.org/doi/10.1126/sciadv.aed0666; https://viterbischool.usc.edu/; https://www.cancer.gov/about-cancer/treatment/research/car-t-cells

References: Science Advances, DOI: 10.1126/sciadv.aed0666

Keywords

CAR-T cell therapy, solid tumors, cancer immunotherapy, focused ultrasound, SHIFTERS, CD19, hypoxia, genetic engineering, glioblastoma, liver cancer, tumor targeting, immune-cell therapy

Unlike conventional CAR T cells, which rely on a single-chain receptor to direct T cells toward tumor antigens, KIR-CAR employs a multi-chain receptor system that more closely mimics the natural biology of NK cells. In this system, one receptor chain specifically recognizes the tumor antigen, while a separate chain modulates the activation signal that instructs the T cell to attack. This division of labor introduces a natural “on-off” switch within the CAR T cells, enabling them to conserve energy and avoid the chronic activation that leads to exhaustion—a major hurdle in ongoing CAR T cell therapy effectiveness. This design innovation not only improves the functional longevity of the therapeutic T cells but also minimizes collateral damage to healthy tissues, addressing a critical unmet need in solid tumor treatment.

The investigational agent, termed SynKIR-110, targets the mesothelin protein, a membrane-bound glycoprotein abundantly expressed on the surface of many solid tumor types including ovarian cancer, mesothelioma, and bile duct cancer. Mesothelin’s limited distribution on normal cells makes it an exceptionally attractive target, enabling precision attack with a reduced risk of off-target toxicity. Patients enrolled in this clinical trial had previously undergone multiple lines of conventional treatment and experienced relapse, underscoring the urgent demand for alternative therapeutic strategies in these populations.

The preliminary safety profile from the first nine patients treated across escalating doses was encouraging, with no dose-limiting toxicities observed—a critical milestone for any new cell therapy. The most common adverse event was low-grade cytokine release syndrome (CRS), which remains one of the most manageable side effects in CAR T therapy. Importantly, no cases of neurotoxicity, often a severe complication known as immune effector cell-associated neurotoxicity syndrome (ICANS), were reported. These findings illustrate that the multi-chain KIR-CAR design may inherently mitigate some hallmark toxicities that have constrained the broader application of CAR T cells to solid tumors.

Efficacy signals are emerging even at the lower dose cohorts, a promising indication that the therapy effectively harnesses the immune system to stabilize or shrink tumor burden. One patient at the highest dose achieved a sustained partial response, while several others demonstrated disease stabilization. Peripheral blood analysis showed a dose-dependent increase in peak CAR T cell proliferation, reinforcing the mechanism’s capacity to expand and persist within the hostile tumor microenvironment—a milestone often elusive in solid tumor CAR T approaches due to immune suppression and exhaustion.

The conceptual underpinning of this new paradigm hearkens back to the distinct advantages of NK cell biology, which employs a balance of activating and inhibitory receptors to finely tune immune responses and avoid overactivation. By borrowing this strategy, KIR-CAR T cells can “rest” between activation peaks, reducing metabolic strain and preserving cellular function over time. This balances therapeutic potency with safety, potentially broadening applicability beyond hematologic malignancies—which have been the primary beneficiaries of CAR T technology—to patients battling deeply infiltrative solid tumors.

The ongoing multi-center Phase I clinical trial is sponsored by Verismo Therapeutics, a spinout company originating from the University of Pennsylvania’s Perelman School of Medicine and its Center for Cellular Immunotherapies. This institution has been at the forefront of pioneering cutting-edge immunotherapies, including the earliest FDA-approved CAR T cell products for blood cancers. The collaboration signals a robust translational effort aimed at overcoming historic barriers that have limited CAR T cell success against solid tumors.

Eligibility criteria for this trial prioritized patients with confirmed mesothelin-expressing cancers who had undergone at least one prior line of standard care and experienced disease relapse. This stringent patient selection underscores the challenging clinical context where SynKIR-110 is being tested—patients who have exhausted conventional therapeutic options and often face grim prognoses. By carefully escalating doses and monitoring safety and biological responses, the trial aims to identify the maximum tolerated dose, a prerequisite for future efficacy-driven studies.

Looking ahead, the expansion of this trial to include up to 42 patients promises deeper insights into both the therapeutic window and long-term clinical benefits of KIR-CAR T cell therapy. Researchers anticipate that increased enrollment and further dose optimization will enhance response rates and durability. There is cautious optimism within the scientific community that this unique CAR design could circumvent limitations such as T cell exhaustion and immune-related adverse effects that have historically hampered efforts to translate CAR T therapy beyond hematologic malignancies.

The innovation of an “on-off” switch within engineered immune cells may represent a fundamental leap forward in cellular therapy engineering. By refining control over T cell activation both spatially and temporally, KIR-CAR technology introduces a sophisticated immunologic circuit that empowers cells to engage tumors more judiciously and sustainably. Such advances have the potential to reshape the therapeutic landscape for intractable solid tumors that lack effective, targeted treatment options.

Notably, this study reinforces the growing recognition that the next generation of immunotherapies will emerge from more nuanced reengineering of immune cell signaling pathways. Leveraging multi-chain receptor models and NK cell biology principles enables the creation of “smarter” CAR T cells capable of adapting dynamically to their environment. These approaches stand in stark contrast to earlier, “always-on” CAR designs that often led to rapid T cell exhaustion or systemic toxicities.

While additional studies are essential to confirm these early clinical findings, the SynKIR-110 trial underscores the exciting potential for receptor systems inspired by nature to improve the specificity, safety, and durability of cell-based immunotherapies. This is a pivotal moment in cancer research, where decades of foundational science are converging with innovative engineering to unlock previously unreachable treatment goals and bring hope to patients with cancers once deemed untreatable.

In summary, the initial clinical experience with KIR-CAR T cell therapy represents a landmark step in the evolution of immuno-oncology. By combining NK cell receptor biology with advanced gene engineering, SynKIR-110 is pioneering a promising new frontier in the treatment of mesothelin-expressing solid tumors. As clinical evaluation advances, this approach may broaden the paradigm for how we harness the immune system against cancer, potentially ushering in safer, more efficacious, and long-lasting therapies for patients facing limited therapeutic options.

Subject of Research: CAR T Cell Therapy for Solid Tumor Cancers Using NK Cell Receptor-Based Design
Article Title: Novel KIR-CAR T Cell Therapy Shows Safety and Early Efficacy Signals in Advanced Solid Tumor Trial
News Publication Date: 2026
Web References:

• STAR-101 Phase 1 Clinical Trial (NCT05568680)
• American Association for Cancer Research Annual Meeting
• Faculty Profile – Janos L. Tanyi, MD, PhD
  Keywords: Chimeric antigen receptor therapy, Cancer immunotherapy, Solid tumors, CAR T cell exhaustion, Natural killer cells, Mesothelin, Ovarian cancer, Mesothelioma, Cholangiocarcinoma, Cellular immunotherapy, Dose-escalation clinical trial, Immune-related adverse events

Recent groundbreaking research has introduced a novel approach to conquering these inherent challenges in solid tumor immunotherapy. Scientists have engineered a new generation of ultra-sensitive CAR T cells designed to detect exceedingly low levels of the tumor-associated antigen CD70, a protein that is aberrantly overexpressed across a range of solid tumors but exhibits pronounced heterogeneity in its expression pattern among different tumor cells. This heterogeneity has historically limited the effectiveness of CAR T cells, as conventional receptors fail to recognize tumor cells expressing CD70 beneath the detection threshold.

Building on intricate patient-derived xenograft models that recapitulate the uneven CD70 distribution observed in kidney cancer patients, the research team led by Sophie Hanina uncovered a spectrum of CD70 expression within tumors. Intriguingly, even cells categorized as CD70-negative harbored low but significant amounts of this antigen, insufficient to trigger elimination by existing CAR T modalities. This nuanced understanding of antigen distribution underscored the necessity for enhanced receptor sensitivity to broaden the therapeutic window against solid tumors.

The innovation came with the development of a highly selective and sensitive CAR construct termed the HLA-independent T cell (HIT) receptor. This advanced chimeric receptor transcends the limitations of conventional CARs by detecting minimal antigenic presence, enabling immune cells to target and eradicate tumor populations with diverse CD70 expression confidently. Preclinical models using mice and cultured cells demonstrated that CD70-HIT T cells achieved complete and sustained tumor clearance across renal, ovarian, and pancreatic cancer models, despite the patchy antigen expression characteristic of these malignancies.

This remarkable efficacy repositions CD70 as a prime pan-cancer target, opening new avenues for treating an array of solid tumors previously thought refractory to CAR T cell intervention. The authors propose the HIT receptor design as a blueprint for identifying additional “stealth” tumor antigens—those expressed at levels traditionally considered subthreshold for immunotherapeutic targeting—thereby expanding the horizon for precision-engineered cancer treatments.

At the molecular level, the HIT receptor’s enhanced sensitivity stems from refined antigen-binding kinetics and signal transduction efficiency, allowing T cells to be activated by a fractional antigen presence without compromising specificity. Such design ingenuity mitigates the risk of off-tumor toxicity, a significant concern when targeting antigens with low differential expression between cancerous and healthy tissues.

Importantly, this research aligns with a growing recognition that tumor heterogeneity is a formidable barrier to uniform cancer eradication. The capacity to detect and respond to low-density antigens provides a strategic advantage in outmaneuvering tumor escape mechanisms, which often exploit antigen loss or modulation to evade immune surveillance. By forcing the immune system’s hand through highly sensitive recognition, HIT CAR T cells reduce the likelihood of resistant tumor clones emerging.

The translational potential of this work is profound. Given the prevalence of CD70 expression across more than twenty solid tumor types, as documented in the study, CD70-targeted HIT CAR T therapy could form a backbone for multifaceted treatment regimens. These therapies might be integrated with checkpoint inhibitors, chemotherapy, or radiotherapy to orchestrate comprehensive tumor destruction.

From a clinical development standpoint, the HIT CAR T cell platform invites a reevaluation of antigen thresholds considered viable for targeting, suggesting that the therapeutic index can be expanded through receptor engineering rather than antigen discovery alone. Future investigations will undoubtedly focus on the safety profile of HIT CAR T cells in patient trials, durability of responses, and potential mechanisms underlying observed tumor eradication.

Moreover, this innovative approach fosters renewed optimism in addressing tumor antigen heterogeneity systematically. By harnessing receptor sensitivity as a modifiable parameter, immunotherapies can be tailored not only to canonical tumor antigens but also to those previously dismissed due to expression variability or low abundance.

In conclusion, the advent of CD70-HIT CAR T cells signifies a critical stride toward overcoming the intrinsic challenges of solid tumor immunotherapy. This strategy exemplifies how deep molecular characterization of tumor antigen landscapes combined with cutting-edge receptor design can redefine boundaries for immune targeting, potentially offering lasting remissions where few effective options previously existed.

As the oncology research community eagerly anticipates clinical validation, the current findings provide a compelling proof-of-concept that sensitive CAR engineering could reshape cancer treatment paradigms, transforming solid tumor immunotherapy from a promising idea into a clinical reality.

Subject of Research: Development of ultra-sensitive CAR T cells targeting heterogeneous CD70 expression in solid tumors.

Article Title: Sensitive CAR T cells redefine targetable CD70 expression in solid tumors

News Publication Date: 26-Feb-2026

Web References: 10.1126/science.adv7378

Keywords

CAR T cells, solid tumors, CD70, immunotherapy, tumor heterogeneity, HIT receptor, patient-derived xenograft, kidney cancer, ovarian cancer, pancreatic cancer, tumor antigen sensitivity, chimeric antigen receptor.

Conventional T cell therapies, including CAR-T cells and T cell receptor (TCR) therapies, have shown remarkable clinical responses in certain blood cancers but face significant challenges when applied to solid tumors. A major hurdle involves the transient nature of infused T cells—they often lose efficacy as the immune cells either become exhausted or die off after a limited period. The UCLA team sought to address this challenge by reprogramming the patient’s hematopoietic stem cells to continuously generate fresh, cancer-specific T cells, potentially sustaining an anti-tumor immune response indefinitely. This strategy, in essence, implants a self-renewing immune system upgrade.

The clinical trial, published in Nature Communications, represents a first-in-human demonstration of this approach. Led by Dr. Theodore Scott Nowicki, alongside collaborators Dr. Antoni Ribas, Dr. Owen Witte, Dr. Donald Kohn, Dr. Lili Yang, and Dr. David Baltimore, the study leverages sophisticated gene therapy techniques to genetically modify stem cells with receptors that redirect T cells to recognize cancer-specific markers. Following genetic engineering, these modified stem cells are reintroduced into the patient via a bone marrow transplant, enabling long-term immune surveillance and attack against tumor cells.

One of the pivotal decisions in the trial involved targeting NY-ESO-1, a cancer-testis antigen that is selectively expressed in several tumor types, including melanoma and synovial sarcoma, while remaining largely absent in normal adult tissues. This selectivity reduces the risk of off-target effects and collateral damage to healthy cells, a critical consideration in the design of safe immunotherapies. Synovial sarcomas, in particular, exhibit high expression of NY-ESO-1, making this malignancy an ideal candidate for the pilot clinical trial.

The patient cohort consisted of individuals suffering from aggressive sarcomas, where conventional therapies often fall short and relapse rates are notoriously high. In these patients, even after chemotherapy or surgical resection, disease recurrence is common and treatment options remain limited. By focusing on this difficult-to-treat population, the study aimed to validate the feasibility and safety of implanting genetically modified stem cells as a durable cancer-fighting strategy.

Early outcomes from the trial were encouraging. Researchers observed successful engraftment of the engineered stem cells within the patients’ bone marrow, accompanied by the sustained production of cancer-specific T cells detectable for several months post-treatment. In one noteworthy case, tumor regression was documented, along with the persistence of newly generated immune cells that continuously surveilled and fought the malignancy. Imaging and molecular assays confirmed that the reprogrammed stem cells had taken root and were functioning as intended within the host.

Dr. Ribas emphasized that this pilot study substantiates the concept that the human immune system can be genetically programmed via stem cells to mount a renewable, cancer-directed response. This realization builds upon prior preclinical work from UCLA and Caltech laboratories, highlighting the translational potential of gene therapy techniques in regenerative immunology. Although these findings herald a major advance, the investigators caution that the approach remains experimental and complex, requiring sophisticated clinical management including stem cell collection, gene editing, conditioning chemotherapy, and careful post-transplant monitoring.

The procedure’s complexity and inherent risks underscore the necessity for specialized institutions and patient selection to maximize safety and efficacy. Nonetheless, parallels can be drawn to the early years of bone marrow transplantation, which initially presented logistical and clinical challenges but ultimately transformed patient care through technological refinement and experience accumulation. As such, the UCLA team anticipates that with further development, this therapy could become more accessible and streamlined.

Beyond oncology, the implications of using engineered stem cells as an enduring source of specialized immune cells extend to a broad spectrum of diseases. Dr. Nowicki suggests applications could include chronic viral infections like HIV, where long-lasting immune surveillance is critical, as well as autoimmune conditions, where immune modulation might be achieved by retraining the immune system. This modular, stem cell-based immune programming approach opens new avenues far beyond cancer, representing a transformative platform for immune engineering.

Perhaps the most profound takeaway from this research is the demonstration that it is biologically and clinically feasible to create a renewable, personalized immune defense against cancer by reprogramming the patient’s own stem cells. While not yet curative or widely available, this strategy challenges the paradigm of temporary treatments and stimulates vision for future immunotherapies that not only combat tumors but sustainably prevent their recurrence.

This milestone was achieved through a decade-long collaborative effort of over 30 scientists and clinicians, combining expertise in stem cell biology, gene therapy, oncology, and immunology. Acknowledging the extensive foundational work preceding the clinical trial, the investigators hope that this study catalyzes further research and accelerates the pathway toward next-generation immune cell therapies capable of delivering durable cancer control.

Funded by a consortium including the California Institute for Regenerative Medicine, the National Institutes of Health, Hyundai Hope on Wheels, the Tower Cancer Research Foundation, and the Parker Institute for Cancer Immunotherapy, this research exemplifies the power of integrated scientific innovation and cross-disciplinary collaboration. The involvement of faculty from UCLA’s David Geffen School of Medicine, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA Health Jonsson Comprehensive Cancer Center, and the California Institute of Technology underpin the strength of this endeavor.

Looking ahead, the team is optimistic that continued refinement of genetic engineering methods, improved conditioning regimens, and enhanced understanding of tumor immunology will contribute to the broader application and increased safety of this stem cell-based immunotherapy platform. As progress accelerates, this novel paradigm has the potential to significantly shift clinical practice, enabling lifelong immune protection for cancer patients and redefining the ultimate goal of cancer treatment: not just remission, but durable cure and prevention.

Subject of Research: Cancer immunotherapy via genetically engineered hematopoietic stem cells producing tumor-specific T cells.
Article Title: Pioneering Stem Cell Engineering Yields Renewable Cancer-Fighting Immune Cells in Humans
News Publication Date: Not explicitly stated
Web References:

• Nature Communications article
• DOI link
  References: Clinical trial led by Dr. Theodore Scott Nowicki et al., published in Nature Communications in 2025.
  Image Credits: Not specified
  Keywords: Cancer, Sarcoma, Cancer research, Stem cells, Immunotherapy